ProMIS Neurosciences Inc reports results for the quarter ended December 31 - Earnings Summary
31/03/2025 22:30
ProMIS Neurosciences Inc PMN.OQ reported a quarterly adjusted loss of 1 cent per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -29 cents. The mean expectation of two analysts for the quarter was for a loss of 14 cents per share. Wall Street expected results to range from -16 cents to -12 cents per share. Reported revenue was zero; analysts expected zero. ProMIS Neurosciences Inc's reported EPS for the quarter was a loss of 2 cents. The company reported a quarterly loss of $238 thousand. ProMIS Neurosciences Inc shares had fallen by 26.1% this quarter. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy" Wall Street's median 12-month price target for ProMIS Neurosciences Inc is $8.00 This summary was machine generated from LSEG data March 31 at 09:30 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.14 | -0.01 | Beat |
| Sep. 30 2024 | -0.07 | 0.42 | Beat |
| Jun. 30 2024 | -0.14 | -0.13 | Beat |
| Mar. 31 2024 | -0.20 | -0.19 | Beat |